This activity is provided by Med Learning Group.
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2025 Med Learning Group. Built by Divigner. All Rights Reserved.
Payer Considerations in NHL: Updates in the Use of Bispecific Antibodies in DLBCL and FL
Snapshot
Smartcast 1: Importance of bispecific antibodies and interpretation of their efficacy and safety data in the treatment of DLBCL and FL
Smartcast 2: Understanding the place of bispecific antibodies in the treatment armamentarium and monitoring and management of their side effects in practice to treat DLBCL and FL
Snapshot
PROGRAM CHAIR
Halee R. Namanny, PharmD
Hematology Clinical Pharmacist
Huntsman Cancer Institute
University of Utah Healthcare
Salt Lake City, UT
PROGRAM OVERVIEW
This innovative online educational programming is designed to meet the educational needs of payers, clinical pharmacists, medical oncologists, hematologists, nurse practitioners, and other members of the multi-disciplinary oncology care team. Using a combination of slides, infographic data, and a whiteboard animation, we aim to help learners understand the importance of bispecific antibodies including interpretation of their safety and efficacy data, in addressing previously unmet needs in the management of DLBCL and FL. This will help to inform coverage for patients with DLBCL and FL. Additionally, the goal is to familiarize learners with potential adverse events associated with the use of bispecific antibodies and discuss strategies for their monitoring and management in clinical practice.
TARGET AUDIENCE
This activity is designed to meet the educational needs of payers, clinical pharmacists, medical oncologists, hematologists, nurse practitioners, and other members of the multi-disciplinary oncology care team.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the importance of bispecific antibodies in addressing previously unmet needs in the management of DLBCL and FL
- Interpret efficacy and safety data with bispecific antibodies to inform coverage for patients with DLBCL and FL
- Describe appropriate monitoring and management parameters to ensure optimal use of bispecific antibodies for DLBCL and FL in practice
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Halee R. Namanny, PharmD | Nothing to disclose | |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Vaidehee Deshpande, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Mike Milano, MD, has received royalties from Wolters Kluwer (Up ToDate author royalties).
- Kelly Vicci, RN, BSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: April 30, 2025
EXPIRATION DATE: April 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Smartcast 1: Importance of bispecific antibodies and interpretation of their efficacy and safety data in the treatment of DLBCL and FL
PROGRAM CHAIR
Halee R. Namanny, PharmD
Hematology Clinical Pharmacist
Huntsman Cancer Institute
University of Utah Healthcare
Salt Lake City, Utah
PROGRAM OVERVIEW
This podcast will evaluate the role of bispecific antibodies in addressing previously unmet needs in managing diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Additionally, we will review the efficacy and safety data of FDA-approved bispecific antibodies to guide coverage decisions for patients with DLBCL and FL.
TARGET AUDIENCE
This activity is designed to meet the educational needs of payers, clinical pharmacists, medical oncologists, hematologists, nurse practitioners, and other members of the multi-disciplinary oncology care team.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the importance of bispecific antibodies in addressing previously unmet needs in the management of DLBCL and FL
- Interpret efficacy and safety data with bispecific antibodies to inform coverage for patients with DLBCL and FL
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Speaker | Relationships | Manufacturer |
| Halee R. Namanny, PharmD | Has nothing to disclose | |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Vaidehee Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Mike Milano, MD, has received royalties from Wolters Kluwer (UpToDate author royalties).
- Kelly Vicci, RN, BSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please note: This program was completed prior to the May 20-21, 2025, Meeting of the Oncologic Drugs Advisory Committee. The robustness of the efficacy and safety data from the STARGLO trial need to be carefully considered in light of the inconsistent treatment effects across multiple endpoints observed between regions and the applicability of the overall results to a U.S. patient population with R/R DLBCL following at least one line of systemic therapy, who are considered ineligible for autologous stem cell transplantation.
Please listen to the podcast below:
RELEASED DATE: May 09, 2025
EXPIRATION DATE: May 09, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Smartcast 2: Understanding the place of bispecific antibodies in the treatment armamentarium and monitoring and management of their side effects in practice to treat DLBCL and FL
PROGRAM CHAIR
Halee R. Namanny, PharmD
Hematology Clinical Pharmacist
Huntsman Cancer Institute
University of Utah Healthcare
Salt Lake City, Utah
PROGRAM OVERVIEW
This podcast examines the safety and efficacy of bispecific antibodies to guide coverage decisions for patients with DLBCL and FL. It also outlines appropriate monitoring and management strategies to ensure the optimal use of bispecific antibodies in clinical practice.
TARGET AUDIENCE
This activity is designed to meet the educational needs of payers, clinical pharmacists, medical oncologists, hematologists, nurse practitioners, and other members of the multidisciplinary oncology care team.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Interpret efficacy and safety data with bispecific antibodies to inform coverage for patients with DLBCL and FL
- Describe appropriate monitoring and management parameters to ensure optimal use of bispecific antibodies for DLBCL and FL in practice
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Speaker | Relationships | Manufacturer |
| Halee R. Namanny, PharmD | Has nothing to disclose | |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Vaidehee Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Mike Milano, MD, has received royalties from Wolters Kluwer (UpToDate author royalties).
- Kelly Vicci, RN, BSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please note: This program was completed prior to the May 20-21, 2025, Meeting of the Oncologic Drugs Advisory Committee. The robustness of the efficacy and safety data from the STARGLO trial need to be carefully considered in light of the inconsistent treatment effects across multiple endpoints observed between regions and the applicability of the overall results to a U.S. patient population with R/R DLBCL following at least one line of systemic therapy, who are considered ineligible for autologous stem cell transplantation.
Please listen to the podcast below:
RELEASED DATE: May 16, 2025
EXPIRATION DATE: May 16, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.